KYNTRA BIO, INC. Payments to Acquire Debt Securities, Available-for-sale
KYNTRA BIO, INC. (KYNB) reported Payments to Acquire Debt Securities, Available-for-sale of $15.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireAvailableForSaleSecuritiesDebt · last filed 2026-08-13
- KYNTRA BIO, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-06-30 was $3.95M.
- KYNTRA BIO, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2026-03-31 was $11.05M.
- KYNTRA BIO, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-12-31 was $58.12M.
- KYNTRA BIO, INC. payments to acquire debt securities, available-for-sale for the quarter ending 2025-09-30 was $3.04M.
- KYNTRA BIO, INC. payments to acquire debt securities, available-for-sale for fiscal 2025 was $61.16M, a 608.83% increase from fiscal 2024.
- KYNTRA BIO, INC. payments to acquire debt securities, available-for-sale for fiscal 2024 was $8.63M, a 96.57% decline from fiscal 2023.
- KYNTRA BIO, INC. payments to acquire debt securities, available-for-sale for fiscal 2023 was $251.83M, a 53.53% increase from fiscal 2022.
- KYNTRA BIO, INC. payments to acquire debt securities, available-for-sale for fiscal 2022 was $164.02M, a 66.12% decline from fiscal 2021.
| Period end | Payments to Acquire Debt Securities, Available-for-sale 3 month | Payments to Acquire Debt Securities, Available-for-sale 6 month | Payments to Acquire Debt Securities, Available-for-sale 9 month | Payments to Acquire Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $3.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $15.00M 10-Q · filed 2026-08-13 | $73.13M derived: sum of 3 quarters · filed 2026-08-13 | $76.16M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | $11.05M 10-Q · filed 2026-05-12 | $69.18M derived: sum of 2 quarters · filed 2026-05-12 | $72.21M derived: sum of 3 quarters · filed 2026-05-12 | $72.21M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | $58.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $61.16M derived: sum of 2 quarters · filed 2026-03-16 | $61.16M derived: sum of 3 quarters · filed 2026-08-13 | $61.16M 10-K · filed 2026-03-16 |
| 2025-09-30 | $3.04M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $3.04M derived: sum of 2 quarters · filed 2026-08-13 | $3.04M 10-Q · filed 2025-11-10 | $3.04M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | $0.00 10-Q · filed 2026-08-13 | $0.00 derived: sum of 3 quarters · filed 2026-08-13 | $0.00 derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-12 | $0.00 derived: sum of 2 quarters · filed 2026-05-12 | $0.00 derived: sum of 3 quarters · filed 2026-05-12 | $0.00 derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | $0.00 derived: sum of 2 quarters · filed 2026-03-16 | $0.00 derived: sum of 3 quarters · filed 2026-03-16 | $8.63M 10-K · filed 2026-03-16 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $0.00 derived: sum of 2 quarters · filed 2025-11-10 | $8.63M 10-Q · filed 2025-11-10 | $103.25M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $8.63M 10-Q · filed 2025-08-11 | $103.25M derived: sum of 3 quarters · filed 2025-08-11 | $155.91M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $8.63M 10-Q · filed 2025-05-12 | $103.25M derived: sum of 2 quarters · filed 2025-05-12 | $155.91M derived: sum of 3 quarters · filed 2025-05-12 | $257.99M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | $94.62M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | $147.29M derived: sum of 2 quarters · filed 2025-03-17 | $249.36M derived: sum of 3 quarters · filed 2025-03-17 | $251.83M 10-K · filed 2025-03-17 |
| 2023-09-30 | $52.67M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $154.74M derived: sum of 2 quarters · filed 2024-11-12 | $157.21M 10-Q · filed 2024-11-12 | $223.93M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | $102.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $104.54M 10-Q · filed 2024-08-06 | $171.26M derived: sum of 3 quarters · filed 2024-08-06 | $209.44M derived: sum of 4 quarters · filed 2024-08-06 |
| 2023-03-31 | $2.47M 10-Q · filed 2024-05-06 | $69.19M derived: sum of 2 quarters · filed 2024-05-06 | $107.37M derived: sum of 3 quarters · filed 2024-05-06 | $145.58M derived: sum of 4 quarters · filed 2024-05-06 |
| 2022-12-31 | $66.72M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $104.90M derived: sum of 2 quarters · filed 2024-02-26 | $143.11M derived: sum of 3 quarters · filed 2024-02-26 | $164.02M 10-K · filed 2024-02-26 |
| 2022-09-30 | $38.18M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $76.39M derived: sum of 2 quarters · filed 2023-11-06 | $97.30M 10-Q · filed 2023-11-06 | $183.54M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-06-30 | $38.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $59.12M 10-Q · filed 2023-08-07 | $145.36M derived: sum of 3 quarters · filed 2024-02-26 | $276.62M derived: sum of 4 quarters · filed 2024-02-26 |
| 2022-03-31 | $20.91M 10-Q · filed 2023-05-08 | $107.15M derived: sum of 2 quarters · filed 2024-02-26 | $238.41M derived: sum of 3 quarters · filed 2024-02-26 | $308.81M derived: sum of 4 quarters · filed 2024-02-26 |
| 2021-12-31 | $86.23M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $217.50M derived: sum of 2 quarters · filed 2024-02-26 | $287.90M derived: sum of 3 quarters · filed 2024-02-26 | $484.14M 10-K · filed 2024-02-26 |
| 2021-09-30 | $131.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | $201.67M derived: sum of 2 quarters · filed 2022-11-07 | $397.91M 10-Q · filed 2022-11-07 | |
| 2021-06-30 | $70.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $266.65M 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | $196.24M 10-Q · filed 2022-05-09 | |||
| 2020-12-31 | $8.19M 10-K · filed 2023-02-27 | |||
| 2019-12-31 | $411.30M 10-K/A · filed 2022-03-04 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 |